Recent news on

Inspire Reports First Quarter 2007 Financial Results  -  May 9, 2007
PharmaLive.com (press release),Co-promotion revenue from net sales of Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for the first quarter of 2007 was $2.4 million, an increase of

Inspire Announces Webcasts of Presentations at Deutsche Bank and ...  -  26 Apr 2007
Business Wire (press release),Inspire’s US specialty sales force promotes Elestat ® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine

Inspire Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 27, 2007
Genetic Engineering News (press release),Co-promotion revenue from net sales of Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for the fourth quarter of 2006 was $4.2 million, an increase of

Inspire Announces Webcast of Presentation at Cowen and Company’s ...  -  Mar 6, 2007
Business Wire (press release),Inspire’s US specialty sales force promotes Elestat ® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine

Inspire Sees Higher R&D Expenses in 2007  -  Feb 27, 2007
Forbes,Aggregate revenue is expected to range from $40 million to $47 million, based on trends of Elestat and Restasis. Operating expenses are expected to range

Inspire losses double as R&D costs increase  -  Feb 27, 2007
News & Observer,Inspire has a contract with California-based Allergan to sell two Allergan drugs, dry eye treatment Restasis and allergy drug Elestat. For the full year,

Inspire Pharmaceuticals (ISPH) Tops Q4 EPS by 6c, Guides In-line ...  -  Feb 27, 2007
StreetInsider.com (subscription),Based upon current Elestat and Restasis trends and projected operating plans, Inspire expects to record aggregate revenue in the range of $40-$47 million

Losses Increase at Inspire, But Quarterly Report Beats Street ...  -  Feb 27, 2007
WRAL.com,The revenues came largely through Inspire’s co-promotion and sales efforts of the eye drugs Elestat and Restasis. For the year, revenues increased to $37.1

Inspire to Present Data at 2007 American Academy of Allergy ...  -  Feb 23, 2007
PharmaLive.com (press release),Inspire's US specialty sales force currently promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis.

Inspire Announces Webcast of Presentation at Susquehanna ...  -  Feb 22, 2007
PharmaLive.com (press release),Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine

News For Your Web Site  -  Feb 19, 2007
dBusinessNews Triangle (press release),Inspire’s US specialty sales force promotes Elestat® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine

Inspire may license therapy  -  Feb 16, 2007
Durham Herald Sun,Inspire's revenues are generated by its agreement with Allergan to co-promote two of the firm's eye treatments, Elestat and Restasis.

Inspire Provides Cystic Fibrosis Clinical Program Update  -  Jan 16, 2007
Business Wire (press release),Inspire’s US specialty sales force promotes Elestat ® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 6, 2006
dBusinessNews Triad (press release),...“Given my positive experience with the ocular form of epinastine (Elestat®), I am pleased to have the opportunity to evaluate the nasal form of epinastine,�

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional